Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
Accession Number
DB10584
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Other vaccines
Description
Not Available
Synonyms
  • Diphtheria toxoid
  • Diphtheria toxoid adsorbed
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diphtheria ToxoidLiquid50 lfSubcutaneousAventis Pasteur Limited1925-12-312001-07-19Canada
Diphtheria Toxoid for Reaction Test 0.2lf/mlLiquid0.2 lfIntradermalAventis Pasteur Limited1955-01-012000-04-06Canada
Diphtheria Toxoid for Schick Control 0.2lf/mlLiquid0.2 lfIntradermalConnaught Laboratories Ltd.1925-12-311996-09-10Canada
Diphtheria Toxoid Immunization Of ReactorsLiquid4 lfSubcutaneousAventis Pasteur Limited1933-12-312001-07-19Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Adacel TDaPCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2005-06-10Not applicableUs
Adacel TDaP TDaPCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)Injection, suspensionIntramuscularRemedy Repack2015-11-142016-03-29Us
BoostrixCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/0.5mL)SuspensionIntramuscularA-S Medication Solutions2009-07-24Not applicableUs
BoostrixCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2009-07-24Not applicableUs
BoostrixCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/0.5mL)SuspensionIntramuscularA-S Medication Solutions2009-07-24Not applicableUs
CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS PERTACTIN ANTIGEN, and BORDETELLA PERTUSSIS FIMBRIAE 2/3 ANTIGENCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)Injection, suspensionIntramuscularA-S Medication Solutions2005-06-10Not applicableUs
D2t5 Diphtheria and Tetanus Toxoid AdsorbedCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 lf) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf)SuspensionIntramuscularIaf Biovac Inc.1998-06-291999-01-08Canada
DaptacelCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (10 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2002-05-14Not applicableUs
DecavacCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)SuspensionIntramuscularSanofi Pasteur Limited2004-03-242016-05-19Us
Diphtheria and Tetanus Toxoids AdsorbedCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (6.7 [Lf]/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited1984-09-182013-03-18Us
Categories
UNII
IRH51QN26H
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with 2-Methoxyethanol.
25-desacetylrifapentineThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with 25-desacetylrifapentine.
6-Deoxyerythronolide BThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abetimus.
Acetyl sulfisoxazoleThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Acetyl sulfisoxazole.
ActeosideThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Afelimomab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available
ATC Codes
J07AF01 — Diphtheria toxoid
AHFS Codes
  • 36:28.00 — Diphtheria
  • 80:08.00 — Toxoids

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1RecruitingTreatmentGlioblastomas / Malignant Gliomas / Pediatric Brain Tumor / Pediatric Brain Tumor, Recurrent / Pediatric Glioblastoma Multiforme / Recurrent Medulloblastoma1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2CompletedPreventionBacterial Infections; Virus Diseases1
2CompletedPreventionDiphtheria / Pertussis / Poliomyelitis / Tetanus / Viral Hepatitis B1
2CompletedPreventionHaemophilus Influenzae Type B / Neisseria Meningitidis1
2CompletedPreventionInfections, Rotavirus / Rotavirus Gastroenteritis1
2CompletedPreventionMeningitis / Meningococcal Infections1
2RecruitingTreatmentAstrocytoma, Grade IV / GBM / Glioblastoma Multiforme (GBM) / Glioblastomas / Malignant Gliomas1
3CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases2
3CompletedPreventionBacterial Infections / Virus Diseases3
3CompletedPreventionDiphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Whooping Cough1
3CompletedPreventionDiphtheria / Pertussis / Poliomyelitis1
3CompletedPreventionDiphtheria / Pertussis / Poliomyelitis / Rubeola / Tetanus1
3CompletedPreventionDiphtheria / Pertussis / Tetanus2
3CompletedPreventionHaemophilus Influenzae Type B1
3CompletedPreventionHaemophilus Influenzae Type B / Haemophilus Influenzae Type B Infection / Meningococcal Infections / Neisseria Meningitidis1
3CompletedPreventionHaemophilus Influenzae Type B / Neisseria Meningitidis1
3CompletedPreventionInfections, Rotavirus1
3CompletedPreventionInvasive Disease Caused by Neisseria Meningitidis Due to Serogroups A, C, W-135, Y / Meningococcal Infections1
3Not Yet RecruitingPreventionInfections, Pneumococcal / Vaccines, Pneumococcal1
3RecruitingPreventionInfections, Pneumococcal1
4CompletedPreventionAcellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B1
4CompletedPreventionDiphtheria / Haemophilus Infections / Pertussis / Poliomyelitis / Tetanus1
4CompletedPreventionDiphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus1
4CompletedTreatmentPain NOS1
Not AvailableCompletedNot AvailableAcellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B1
Not AvailableCompletedNot AvailableAcellular Pertussis / Diphtheria / Tetanus1
Not AvailableCompletedNot AvailableDiphtheria / Haemophilus Influenzae / Pertussis / Tetanus1
Not AvailableCompletedNot AvailablePertussis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, suspensionIntramuscular
LiquidIntramuscular
LiquidSubcutaneous50 lf
LiquidIntradermal0.2 lf
LiquidSubcutaneous4 lf
Kit
SuspensionIntramuscular
InjectionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on June 14, 2019 18:08